In this study, Dr. Treon and colleagues reported a seven fold increased incidence of WM disease transformation to aggressive lymphoma, and a three-fold increased risk of development of acute leukemia and myelodysplasia in patients who received treatment with a nucleoside analogue (fludarabine or cladribine). This study highlights the importance of carefully weighing risk and benefit in selection of drugs used in the treatment of WM.

Representing one of the longest follow-up studies conducted in WM, this study identified that patients attaining at least a very good partial response (VGPR) had a superior time to progression over patients who did not achieve a VGPR, and highlights the importance of pursuing therapies which can result in deeper categorical response levels in WM. The study also identified increased long term risk of disease transformation and acute leukemia/myelodysplasia.

Dr. Treon's publication in the September 2009 Blood Journal, focused on the importance of individualized care of WM patients. CLICK HERE for the online article, or click on the picture below to download the publication.

This study identified that soluble CD27 (sCD27) levels are elevated in patients with WM, and stimulate mast cells to produce signals (such as CD40L and APRIL) which in turn promote the growth and survival of WM cells. The study also showed that a novel antibody (SGN-70) could be used to block sCD27 signaling and block WM disease growth in mice.